COVID Special Edition: Johnson and Johnson

I wanted to share this J&J info ASAP. Sorry for two posts in one day.

Shout-out to Tori Melendez for her amazing work to help me get this out so quickly.

Johnson & Johnson COVID-19 Vaccine

Efficacy Facts:

· Single-shot vaccine

· 66% effective overall in moderate to severe COVID

· 72% effective in U.S., 66% in Latin America, 57% in South Africa

· Effective 28 days after vaccination (onset of protection seen as early as day 14)

· 85% effective overall of severe COVID in all regions

· Demonstrated complete protection against COVID related hospitalization & death as of day 28

· Provides protection against severe disease in all geographies, ages, and variants

· Protects against SARS-CoV-2 variant from South Africa (B.1.351

· Efficacy against severe cases increased over time with no cases in vaccinated participants reported after day 49

Demography:

· Adults 18 & over

· All ages

· All races

· Study includes 8 countries and 3 continents

· Argentina, Brazil, Chile, Columbia, Mexico, Peru, South Africa, and the United States

· 44% participants in the US (19,302)

· 41% Central & South America (17,905)

· 15% South Africa (6,576)

· 34% over age 60 (14,672)

· 45% female

· 55% male

· 59% Caucasian

· 45% Hispanic

· 19% Black/African American

· 9% Native American

· 3% Asian

· 41% had comorbidities associated with increased risk for severe COVID infection

· Obesity 28.5%

· Type 2 diabetes 7.3%

· Hypertension 10.3%

· HIV 2.8%

Study Design:

· Randomized, double blind, placebo controlled clinical trial

Side-Effects:

· No deaths related to COVID-19 were reported in the vaccine group

· 5 deaths in placebo group were related to COVID-19

· Overall, 16 deaths in placebo group; 3 in vaccine group

· Most common fever, fatigue, headache, muscle ache, pain at injection site

· Breakdown of side-effects by age group:

Ages 18 – 55

Fever – 20 % who received a low dose; 48% who received a high dose

Fatigue – 45% low dose; 70% high dose

Headache – 45% in low dose group; 70% in high dose group

Muscle aches – 40% low dose; 60% high dose

Pain at injection site – 65% low dose; 75% high dose

Aged 65 & Older

Fever – 4% low dose; 10% high dose

Fatigue – 30% low dose; 40% high dose

Headache – 25% low dose; 35% high dose

Muscle aches – 20% low dose; 25% high dose

Pain at the injection site – 40% for both low & high dose groups

*all cases of fever developed within 2 days after immunization and resolved within 1 or 2 days

Note: to date there have been no reports of anaphylaxis and no imbalances between vaccine and placebo on any concerning safety at all. Single-dose vaccine does not need to be frozen and can be stored in a standard refrigerator.